Repligen initiated with an Overweight at Barclays

Barclays initiated coverage of Repligen (RGEN) with an Overweight rating and $150 price target The firm says that as a bioprocessing pure-play, it likes Repligen’s positioning in the current macro tape. Bioprocessing continues to be Barclays’ most preferred subsector given its relative insulation from the major macro headwinds impacting tools, and Repligen is a particularly attractive asset given its heavier weighting towards the clinic, the analyst tells investors in a research note.